6-(trifluoromethoxy)-2-naphthylboronic acid | 870822-82-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-(trifluoromethoxy)-2-naphthylboronic acid
• 英文别名: [6-(trifluoromethyl)-2-naphthyl]boronic acid；2-(Trifluoromethyl)naphthalene-6-boronic acid；[6-(trifluoromethyl)naphthalen-2-yl]boronic acid
• CAS: 870822-82-5
• 化学式: C₁₁H₈BF₃O₂
• 分子量: 239.99
• InChiKey: GQBJXDPQJRYIHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.54
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-(trifluoromethoxy)-2-naphthylboronic acid 、 tert-butyl N-{4-[1-(3-(3,5-dichlorophenyl)-5-{[(trifluoromethyl)sulfonyl]oxy}-1H-pyrazol-1-yl)ethyl]-benzoyl}-β-alaninate 在 四(三苯基膦)钯 、 三乙胺 作用下， 以 乙二醇二甲醚 为溶剂， 反应 0.17h， 生成
  参考文献：
  名称：

  Discovery of a Novel Glucagon Receptor Antagonist N-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes

  摘要：

  A potent, selective glucagon receptor antagonist 9m, N-[(4-{(1S)-1-[3-(3,5-dichlorophenyl) -5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)-carbonyl]-beta-alanine, was discovered by optimization of a previously identified lead. Compound 9m is a reversible and competitive antagonist with high binding affinity (IC50 of 6.6 nM) and functional cAMP activity (IC50 of 15.7 nM). It is selective for glucagon receptor relative to other family B GPCRs, showing IC50 values of 1020 nM for GIPR, 9200 nM for PAC1, and >10000 nM for GLP-1R, VPAC1, and VPAC2. Compound 9m blunted glucagon-induced glucose elevation in hGCGR mice and rhesus monkeys. It also lowered ambient glucose levels in both acute and chronic mouse models: in hGCGR ob/ob mice it reduced glucose (AUC 0-6 h) by 32% and 39% at 3 and 10 mpk single doses, respectively. In hGCGR mice on a high fat diet, compound 9m at 3, and 10 mpk po in feed lowered blood glucose levels by 89% and 94% at day 10, respectively, relative to the difference between the vehicle control and lean hGCGR mice. On the basis of its favorable biological and DMPK properties, compound 9m (MK-0893) was selected for further preclinical and clinical evaluations.

  DOI：

  10.1021/jm300579z
• 作为产物：
  描述：

  在 盐酸 、 水 作用下， 以 丙酮 为溶剂， 反应 16.0h， 生成 6-(trifluoromethoxy)-2-naphthylboronic acid
  参考文献：
  名称：

  Pyrazole derivatives, compositions containing such compounds and methods of use

  摘要：

  揭示了附有萘基团的吡唑类化合物。这些化合物可用于治疗2型糖尿病及相关疾病。还包括药物组合物和治疗方法。

  公开号：

  US20050272794A1

文献信息

• PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
  申请人：Parmee Emma R.

  公开号：US20090176854A1

  公开（公告）日：2009-07-09

  Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

  本发明揭示了连接有萘基团的吡唑类化合物。这些化合物可用于治疗2型糖尿病及相关疾病。还包括制药组合物和治疗方法。
• Discovery of a Novel Glucagon Receptor Antagonist <i>N</i>-[(4-{(1<i>S</i>)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1<i>H</i>-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes
  作者：Yusheng Xiong、Jian Guo、Mari R. Candelore、Rui Liang、Corey Miller、Qing Dallas-Yang、Guoqiang Jiang、Peggy E. McCann、Sajjad A. Qureshi、Xinchun Tong、Shiyao Sherrie Xu、Jackie Shang、Stella H. Vincent、Laurie M. Tota、Michael J. Wright、Xiaodong Yang、Bei B. Zhang、James R. Tata、Emma R. Parmee

  DOI：10.1021/jm300579z

  日期：2012.7.12

  A potent, selective glucagon receptor antagonist 9m, N-[(4-(1S)-1-[3-(3,5-dichlorophenyl) -5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)-carbonyl]-beta-alanine, was discovered by optimization of a previously identified lead. Compound 9m is a reversible and competitive antagonist with high binding affinity (IC50 of 6.6 nM) and functional cAMP activity (IC50 of 15.7 nM). It is selective for glucagon receptor relative to other family B GPCRs, showing IC50 values of 1020 nM for GIPR, 9200 nM for PAC1, and >10000 nM for GLP-1R, VPAC1, and VPAC2. Compound 9m blunted glucagon-induced glucose elevation in hGCGR mice and rhesus monkeys. It also lowered ambient glucose levels in both acute and chronic mouse models: in hGCGR ob/ob mice it reduced glucose (AUC 0-6 h) by 32% and 39% at 3 and 10 mpk single doses, respectively. In hGCGR mice on a high fat diet, compound 9m at 3, and 10 mpk po in feed lowered blood glucose levels by 89% and 94% at day 10, respectively, relative to the difference between the vehicle control and lean hGCGR mice. On the basis of its favorable biological and DMPK properties, compound 9m (MK-0893) was selected for further preclinical and clinical evaluations.
• Pyrazole derivatives, compositions containing such compounds and methods of use
  申请人：Parmee R. Emma

  公开号：US20050272794A1

  公开（公告）日：2005-12-08

  Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

  揭示了附有萘基团的吡唑类化合物。这些化合物可用于治疗2型糖尿病及相关疾病。还包括药物组合物和治疗方法。